30-Second Takeaway
- Genome sequencing is strengthening first-tier diagnostics for rare disease and hereditary hearing loss, including structural and noncoding variants.
- Oligogenic models, proteogenomics, and single-cell maps are refining interpretation of complex trait and cancer risk loci.
- Deep-learning GWAS and organ-aging proteomics highlight new risk markers and pathways for common neurologic and cardiometabolic disease.
Week ending December 13, 2025
Translational genomics and editing tools moving toward clinical impact
First-tier genome sequencing in Korean rare disease families delivers 46% diagnostic yield
Genome sequencing of 3,317 individuals from 1,452 Korean families with suspected rare disorders achieved a molecular diagnosis in 46.2% of families. Clinical management changed in 18.5% of diagnosed cases, demonstrating tangible utility beyond variant discovery. Family-based genome sequencing outperformed singleton testing (48.5% vs 41.5%), supporting trio or multiplex designs when feasible. GS-specific deep intronic, noncoding, complex structural variants and tandem repeat expansions accounted for 14.6% of diagnoses, inaccessible to standard exomes.
Disease-context pQTL mapping nominates causal proteins and improves risk prediction
A large genome–proteome-wide study profiled 2,901 plasma proteins in 7,626 healthy individuals and 28,064 patients across 42 disease states. Investigators identified 25,987 independent pQTLs across 2,224 regions and showed disease-specific pQTLs were more likely to be disease risk variants. Mendelian randomisation implicated 110 high-confidence causal proteins for 21 diseases, including Apolipoprotein(a) in cardiovascular disease and ACE in type 2 diabetes. Risk models combining pQTL-based polygenic scores and protein risk scores discriminated individuals at high risk for 21 disease types.
GCOD detects oligogenic gene combinations contributing to congenital heart defects
GCOD is a simulation-based framework that tests oligogenic gene sets by comparing co-occurring damaging variants in probands versus parental genotypes. Applied to 3,377 congenital heart defect trios, GCOD identified 160 gene pairs over-transmitted to probands but rarely co-occurring in unaffected parents. Stratified and higher-order analyses yielded an additional 6,026 gene sets enriched for heart development pathways and relevant cardiac cell-type markers. Mouse experiments showed Gata6–Por compound heterozygosity increased CHD incidence compared with single hemizygotes, validating predicted interactions.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.